Inhibition of zaleplon metabolism by cimetidine in the human liver: In vitro studies with subcellular fractions and precision-cut liver slices

Xenobiotica

Volumn 32, Issue 10, 2002, Pages 849-862

  Renwick, A B ^a   Ball, S E ^a   Tredger, J M ^a   Price, R J ^a   Walters, D G ^a   Kao, J ^a   Scatina, J A ^a   Lake, B G ^a  

^a TNO BIBRA International Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; CIMETIDINE; CYTOCHROME P450 3A; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ZALEPLON;

ARTICLE; CELL FRACTIONATION; DRUG INHIBITION; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KINETICS; LIVER METABOLISM; LIVER MICROSOME; LIVER SLICE;

ACETAMIDES; CIMETIDINE; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; INHIBITORY CONCENTRATION 50; KINETICS; LIVER; MODELS, CHEMICAL; PYRIMIDINES; SUBCELLULAR FRACTIONS;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0036794380     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250210158221     Document Type: Article

References (29)

1. Acheampong, A. A., Chien, D.-S., Lam, S., Vekich, S., Breau, A., Usansky, J., Harcourt, D., Munk, S. A., Nguyen, H., Garst, M. and Tang-Liu, D., 1996, Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica, 26, 1035-1055.
2. Andersson, T. B., Sjöberg, H., Hoffmann, K.-J., Boobis, A. R., Watts, P., Edwards, R. J., Lake, B. G., Price, R. J., Renwick, A. B., Gómez-Lechón, M. J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Goldfarb, P. S., Lewis, D, F. V., Corcos, L., Guillouzo, A., Taavitsainen, P. and Pelkonen, O., 2001, An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metabolism and Disposition, 29, 712-720.
3. Beamand, J. A., Price, R. J., Cunninghame, M. E. and Lake, B. G., 1993, Culture of precision-cut liver slices: effect of some peroxisome proliferators. Food and Chemical Toxicology, 31, 137-147.
4. Beer, B., Ieni, J. R., Wu, W.-H., Clody, D., Amorusi, P., Rose, J., Mant, T., Gaudreault, J., Cato, A. and Stern, W., 1994, A placebo-controlled evaluation of single, escalating doses of CL-284,846, a non-benzodiazepine hypnotic. Journal of Clinical Pharmacology, 34, 335-344.
5. Chaudhary, I., Demalo, W. and Kantrowitz, J., 1994, Species comparison of in vitro and in vivo metabolism of CL-284,846, a non-benzodiazepine sedative/hypnotic agent. Pharmaceutical Research, 11, S391.
6. Clarke, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202.
7. Cornish-Bowden, A., 1974, A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochemical Journal, 137, 143-144.
8. Dixon, M., 1953, The determination of enzyme inhibitor constants. Biochemical Journal, 55, 170-171.
9. Houston, J. B. and Carlile, D. J., 1997, Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews, 29, 891-922.
10. Houston, J. B. and Kenworthy, K. E., 2000, In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition, 28, 246-254.
11. Kawashima, K., Hosoi, K., Naruke, T., Shiba, T., Kitamura, M. and Watabe, T., 1999, Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metabolism and Disposition, 27, 422-428.
12. Lake, B. G., 1987, Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism. In K. Snell and B. Mullock (eds), Biochemical Toxicology: A Practical Approach (Oxford: IRL Press), pp. 183-215.
13. Lake, B. G., Ball, S. E., Kao, J., Renwick, A. B., Price, R. J. and Scatina, J. A., 2002, Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica, 32, 835-847.
14. Lin, J. H. and Lu, A. Y. H., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361-390.
15. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
16. Pelkonen, O., Myllynen, P., Taavitsainen, P., Boobis, A. R., Watts, P., Lake, B. G., Price, R. J., Renwick, A. B., Gómez-Lechón, M.-J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S. and Lewis, D. F. V., 2001, Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica, 31, 321-343.
17. Rashidi, M. R., Smith, J. A., Clarke, S. E. and Beedham, C., 1995, Inhibition of human and guinea-pig liver aldehyde oxidases in-vitro. Journal of Pharmacy and Pharmacology, 47, 1090.
18. Renwick, A. B., Mistry, H., Ball, S. E., Walters, D. G., Kao, J. and Lake, B. G., 1998, Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 28, 337-348.
19. Robertson, I. G. C. and Bland, T. J., 1993, Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochemical Pharmacology, 45, 2159-2162.
20. Rodrigues, A. D., Ferrero, J. L., Amann, M. T., Rotert, G. A., Cepa, S. P., Surber, B. W., Machinist, J. M., Tich, N. R. Sullivan, J. P., Garvey, D. S. Fitzgerald, M. and Arneric, S. P., 1994, The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, Cynomolgus monkeys, and humans. Drug Metabolism and Disposition, 22, 788-798.
21. Rosen, A. S., Fournie, P., Darwish, M., Danjou, P. and Troy, S. M., 1999, Zaleplon pharmacokinetics and absolute bioavailability. Biopharmaceutics and Drug Disposition, 20, 171-175.
22. Smith, S. R. and Kendall, M. J., 1988, Ranitidine versus cimetidine: a comparison of their potential to cause clinically important drug interactions. Clinical Pharmacokinetics, 15, 44-56.
23. Somogyi, A. and Muirhead, M., 1987, Pharmacokinetic interactions of cimetidine 1987. Clinical Pharmacokinetics, 12, 321-366.
24. Steensma, A., Beamand, J. A., Walters, D. G., Price, R. J. and Lake, B. G., 1994, Metabolism of coumarin and 7-ethoxycoumarin by rat, guinea pig, Cynomolgus monkey and human precision-cut liver slices. Xenobiotica, 24, 893-907.
25. Tanaka, E., 1998, Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23, 403-416.
26. Ueng, Y.-F., Kuwabara, T., Chun, Y.-J. and Guengerich, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370-381.
27. Worboys, P. D., Bradbury, A. and Houston, J. B., 1997, Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metabolism and Disposition, 25, 460-467.
28. Wrighton, S. A. and Ring, B. J., 1994, Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmaceutical Research, 11, 921-924.
29. Wu, W. H., Dicioccio, A. T., Demaio, W., Amorusi, P., Tonelli, A. P. and Mayer, P. R., 1996, Mass balance and pharmacokinetics of zaleplon, a non-benzodiazepine sedative/hypnotic, in man. Pharmaceutical Research, 13, S487.